With over 9000 people being diagnosed with CML in 2024, more than 10,000 with MDS or MPD, nearly 6000 with GIST, and upwards of 6500 expected to be diagnosed with ALL by the end of the year ...

The Food and Drug Administration (FDA) has approved Imkeldi, an oral solution formulation of imatinib. Imkeldi is indicated to treat chronic myeloid leukemia, acute lymphoblastic leukemia ...

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial ...

imatinib for 3 years and regular follow up (standard treatment) imatinib for 5 years and regular follow up (extended treatment) Neither you nor your doctor are able to decide which group you are in.

Karimi M, Bahadoram M, Mafakher L, Rastegar M. Impact of imatinib on reducing the painful crisis in patients with sickle cell disease. Hematol Transfus Cell Ther . Published online August 10, 2023 ...

MARLBOROUGH, Mass., June 21, 2023 /PRNewswire/ -- AssayQuant® Technologies, Inc. introduces KinSight™ Kinome Profiling Services providing superior results including kinetic insights into ...

In the trial, investigators are evaluating ponatinib vs imatinib in combination with reduced-intensity chemo in this newly diagnosed patient population. The study randomized patients 2:1 to receive ...

Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma. ... Imatinib is a multikinase inhibitor targeting PDGFR, ABL, c-KIT, that is already used ...

Crenolanib was significantly more potent than imatinib in inhibiting the kinase activity of PDGFRA via the activation loop of exon 18: D842I, D842V, D842Y, DI842-843IM, and deletion I843. In vitro ...

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.

Aerami Therapeutics announces Orphan Drug designation for imatinib for the treatment of pulmonary arterial hypertension. News release. Aerami Therapeutics, Inc. Accessed August 25, 2021.

Our combined study of kinome profiling coupled with Tyro3 inhibitor development revealed that the kinome profiles between NHL subtypes contain significant ... Imatinib compared with interferon and low ...